Company / Shareholders' Equity
Summit Therapeutics Inc. Shareholders' Equity History
FY2019-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Shareholders' Equity
$658.9M
FY2025
5-year range
$77.7M / $658.9M
FY2021-FY2025
Trend
+69.5%
vs FY2024
Sector context
#68 of 213
Health Care
What the data says
At $659M, Summit Therapeutics Inc.'s shareholders' equity ranks #68 of 213 in the Health Care sector. Improved from $78M to $659M over the past 2 years.
Based on SEC 10-K filings.
$659M in FY2025 with a 5-year CAGR of +52.7%.
Improved from $78M to $659M over the past 2 years.
Health Care sector context is included.
Shareholders' Equity over time
Growth rates
- 3-Year CAGR
- +99.3%
- 5-Year CAGR
- +52.7%
- 10-Year CAGR
- -
Sector benchmark
#68 of 213 in Health CareTop 32% of 213This company $658.9M Sector average $2.5B
▼
-74.2% below sector average
Key checks
Key Insights
- 5-year CAGR of +52.7%, indicating consistent growth.
- In FY2025, shareholders' equity increased 69.5% year-over-year.
- Ranks #68 out of 213 companies in the Health Care sector.
- Lowest shareholders' equity in the period was in FY2023.
Company context
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Shareholders' EquityValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $658.9M | +69.5% |
| FY2024 | $388.7M | +400.4% |
| FY2023 | $77.7M | -6.7% |
| FY2022 | $83.3M | +0.0% |
| FY2021 | $83.3M | +4.8% |
| FY2020 | $79.5M | +0.7% |
| FY2019 | $78.9M | - |
| FY2018 | - | - |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026